These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16798546)

  • 1. Diagnosing and managing infection in CF.
    Ratjen F
    Paediatr Respir Rev; 2006; 7 Suppl 1():S151-3. PubMed ID: 16798546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Ratjen F
    Curr Opin Pulm Med; 2006 Nov; 12(6):428-32. PubMed ID: 17053493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary infections in children with cystic fibrosis.
    Stutman HR; Marks MI
    Semin Respir Infect; 1987 Sep; 2(3):166-76. PubMed ID: 3317617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
    Coman G; Petraru E; Dahorea C; Anton DT
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.
    Aaron SD
    Paediatr Respir Rev; 2007 Sep; 8(3):256-61. PubMed ID: 17868924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
    Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
    Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations.
    Keays T; Ferris W; Vandemheen KL; Chan F; Yeung SW; Mah TF; Ramotar K; Saginur R; Aaron SD
    J Cyst Fibros; 2009 Mar; 8(2):122-7. PubMed ID: 19064337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiologic and therapeutic aspects of Staphylococcus aureus in cystic fibrosis patients.
    Bauernfeind A; Hörl G; Przyklenk B
    Scand J Gastroenterol Suppl; 1988; 143():99-102. PubMed ID: 3164518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibiotic treatment of lung disease in cystic fibrosis].
    Biasini GC; Pistocchi E; Miano A
    Pediatr Med Chir; 1983; 5(4):157-60. PubMed ID: 6647075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy.
    Colombo C; Costantini D; Rocchi A; Cariani L; Garlaschi ML; Tirelli S; Calori G; Copreni E; Conese M
    Pediatr Pulmonol; 2005 Jul; 40(1):15-21. PubMed ID: 15858808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced sputum compared to bronchoalveolar lavage in young, non-expectorating cystic fibrosis children.
    Blau H; Linnane B; Carzino R; Tannenbaum EL; Skoric B; Robinson PJ; Robertson C; Ranganathan SC
    J Cyst Fibros; 2014 Jan; 13(1):106-10. PubMed ID: 23806622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of early Pseudomonas aeruginosa infection.
    Høiby N; Frederiksen B; Pressler T
    J Cyst Fibros; 2005 Aug; 4 Suppl 2():49-54. PubMed ID: 16023416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis infections: treatment strategies and prospects.
    George AM; Jones PM; Middleton PG
    FEMS Microbiol Lett; 2009 Nov; 300(2):153-64. PubMed ID: 19674113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T
    Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Ratjen F; Walter H; Haug M; Meisner C; Grasemann H; Döring G
    Pediatr Pulmonol; 2007 Mar; 42(3):249-55. PubMed ID: 17243185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C; Hall M; Conway S; Peckham D; Denton M
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.